Diabetes therapeutics such as glucose and weight control are major physiological functions of the new glucagon-like peptide-1 (GLP-1) agonists. But is there evidence to suggest that GLP-1 may also have some cardiovascular benefits? Join host Dr. Steven Edelman and Dr. John Buse, professor of medicine at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the emerging cardiovascular actions of incretin hormones.
Do Incretins Play An Important Role In the Cardiovascular System?

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Diabetes therapeutics such as glucose and weight control are major physiological functions of the new glucagon-like peptide-1 (GLP-1) agonists. But is there evidence to suggest that GLP-1 may also have some cardiovascular benefits? Join host Dr. Steven Edelman and Dr. John Buse, professor of medicine at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the emerging cardiovascular actions of incretin hormones.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Innovations in the Management of Hemolytic Disease of the Fetus and Newborn: The Role of the Neonatal Fc Receptor (FcRn) Pathway
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
M3: Managing the Cardiometabolic Risk in MASH
Love Story: Lipid Education for Women’s Heart Health
HF Management for Patients with Comorbid Conditions
Level Up Your Skills: Tailoring Management of HF
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
Navigating Myasthenia Gravis in Adolescents and Young Adults
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?